Abstract: The application relates to prodrugs comprising a drug molecule connected by a protease-cleavable peptide linker to a binder, which reversibly inhibits a biological activity of the drug molecule, and to the inhibitory binders themselves. Also described are nucleic acids encoding the recombinant proteins described herein, and methods of making said recombinant proteins, as well as methods of treatment and medical uses of the recombinant proteins.

Abstract: The present invention relates to designed ankyrin repeat domains having a reduced isoelectric point (pI) and/or having a reduced number of basic amino acid residues. The invention also provides such repeat domains linked to a drug moiety, for example a radionuclide or a cytotoxic agent. The invention furthermore provides methods for producing such repeat domains, as well as the use of such repeat domains in therapeutic and/or diagnostic methods. In addition, the invention provides recombinant proteins comprising such repeat domains, nucleic acids encoding such repeat domains or recombinant proteins, pharmaceutical compositions comprising such repeat domains, recombinant proteins nucleic acids, recombinant expression vectors and host cells, and the use of such proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer.

Abstract: The present invention relates to compositions comprising a binding moiety and a drug molecule, wherein said binding moiety reversibly binds to said drug molecule to form a prodrug complex that slowly releases the drug molecule upon administration in vivo. The present invention further relates to methods of forming such compositions and to methods of treatment using such compositions. Also described are binding moieties, nucleic acids encoding said binding moieties and methods of making these using host cells.